May 06, 2026 (MLN): Citi Pharma Ltd.'s (PSX:CPHL) Board of Directors, approved a proposal to acquire the entire 100% shareholding of Pakheim International Pharmaceuticals (Private) Limited, along with its associated assets, licenses, and operations.

The consideration for the transaction remains subject to formal approval from the concerned authorities, according to the company’s on PSX.

Pakheim International Pharmaceuticals is engaged in pharmaceutical manufacturing and holds multiple DRAP-registered products, backed by an established production facility.

The acquisition is aimed at strengthening Citi Pharma's manufacturing capacity, expanding its product portfolio, and broadening its market footprint, while generating operational synergies and long-term strategic value.

The transaction is conditional upon the completion of legal, financial, and tax due diligence, along with all requisite regulatory approvals under applicable laws. Financing for the deal will be arranged through a combination of internal cash resources and available banking facilities.

Copyright